c-crbB2 gene amplification and protein expression in ovarian epithelial tumors: Evaluation of their respective prognostic significance by multivariate analysis
✍ Scribed by Anne Fajac; Jean Benard; Catherine Lhomme; Annie Rey; Pierre Duvillard; France Rochards; Jean-Francois Bernaudin; Guy Riou
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- French
- Weight
- 849 KB
- Volume
- 64
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
c-erbB2 gene amplification or over-expression has been reported in ovarian cancer, but their prognostic value remains conflicting. To investigate the respective prognostic significance of c-erbB2 gene amplification and protein over-expression, tumor samples were obtained from 65 patients with ovarian adenocarcinoma (9 FlGO stage I, 7 stage S l , 38 stage 111 and I I stage IV) followed up for a median period of 7 I months. c-erbB2 gene amplification (22.5 a.u.) was detected in 9/65 (14%) adenocarcinomas and in none of 5 benign and 8 borderline ovarian epithelial tumors also analyzed. Specimens from 52 of the 65 adenocarcinomas were available for immunohistochemical analysis. c-erbB2 protein expression was observed in 23/52 (44%) adenocarcinomas. No correlation was found between c-erbB2 gene copy number and protein expression. There was no correlation of c-erbB2 gene copy number or protein expression with any of the clinico-pathological factors analyzed (i.e., FlGO stage, histological type, histological grade and residual tumor). On univariate analysis, c-erbB2 gene amplification was associated with poorer survival ( p = 0.04). However, in the multivariate analysis of clinico-pathological factors and c-erb82 gene copy number, c-erbB2 gene amplification did not retain 'According to FIGO criteria (Kottmeier, 1989).-2According to WHO criteria (Serov and Scully, 1973).-3Volume of tumor remaining after initial surgery (Hoskins, 1989